Want to see JP:4586 full AI Analyst Report?
Top Page
Medrx Co., Ltd.
(4586)
Select Model
Select Model
Rating:46Neutral
Price Target:
¥67.00
▲(1.52% Upside)
Action:Reiterated
Date:07/17/26
The score is held down primarily by persistent deep losses and ongoing cash burn, which outweigh the encouraging 2025 revenue rebound and strong gross margins. Technical signals are mixed—moderate near-term momentum but a weak longer-term trend—while valuation is constrained by negative earnings and no stated dividend yield.
Positive Factors
High gross margins
Sustained gross margins near 85–90% across recent years indicate structurally high product-level profitability tied to the firm’s transdermal formulation capabilities. High gross margin provides durable gross cash generation potential as revenue scales, supporting long-term product investment.
Negative Factors
Persistent negative operating/ free cash flow
Consistent yearly negative operating and free cash flow means the company is not self-funding and must rely on external financing or shareholder capital. Over a 2–6 month horizon this structural cash burn raises financing risk and constrains strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
High gross margins
Sustained gross margins near 85–90% across recent years indicate structurally high product-level profitability tied to the firm’s transdermal formulation capabilities. High gross margin provides durable gross cash generation potential as revenue scales, supporting long-term product investment.
Read all positive factors
Medrx Co., Ltd. (4586) vs. iShares MSCI Japan ETF (EWJ)
Market Cap
¥4.47B
Dividend YieldN/A
Average Volume (3M)2.57M
Price to Earnings (P/E)―
Beta (1Y)1.33
Revenue Growth167.44%
EPS Growth49.38%
CountryJP
Employees21
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-14.23
Shares Outstanding67,729,800
10 Day Avg. Volume1,116,360
30 Day Avg. Volume2,574,156
Financial Highlights & Ratios
PEG Ratio1.03
Price to Book (P/B)2.83
Price to Sales (P/S)45.31
P/FCF Ratio-5.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Medrx Co., Ltd. Business Overview & Revenue Model
Company Description
Established in 2002 and headquartered in Higashikagawa, Japan, MedRx Co., Ltd is a pharmaceutical firm focused on developing drug formulations. The company primarily provides pharmaceutical products in Japan that leverage transdermal absorption sy...
How the Company Makes Money
null...
Medrx Co., Ltd. Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
63
Positive
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 121.00M | 128.08M | 257.92M | 29.53M | 59.48M | 8.35M |
| Gross Profit | 109.78M | 113.01M | 219.19M | -18.43M | 10.45M | -54.25M |
| EBITDA | -868.59M | -928.13M | -754.62M | -888.00M | -1.05B | -1.00B |
| Net Income | -858.85M | -937.37M | -806.76M | -932.90M | -1.11B | -1.06B |
Balance Sheet | ||||||
| Total Assets | 1.74B | 2.16B | 2.27B | 2.05B | 1.40B | 2.11B |
| Cash, Cash Equivalents and Short-Term Investments | 1.14B | 1.75B | 1.98B | 1.72B | 994.02M | 1.70B |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 149.79M | 108.54M | 107.00M | 127.52M | 185.56M | 153.10M |
| Stockholders Equity | 1.59B | 2.05B | 2.17B | 1.92B | 1.21B | 1.96B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | -970.86M | -803.00M | -913.76M | -1.08B | -926.23M |
| Operating Cash Flow | 0.00 | -888.11M | -803.00M | -913.00M | -1.07B | -923.69M |
| Investing Cash Flow | 0.00 | -82.75M | -3.15M | -759.00K | -1.96M | -2.54M |
| Financing Cash Flow | 0.00 | 745.09M | 1.07B | 1.64B | 356.31M | 815.91M |
Medrx Co., Ltd. Technical Analysis
Neutral
66.00
Price Trends
60.38
Positive
67.53
Negative
91.03
Negative
Market Momentum
1.13
Positive
53.63
Neutral
58.33
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4586, the sentiment is Neutral. The current price of 66 is equal to the 20-day moving average (MA) of 66.00, above the 50-day MA of 60.38, and below the 200-day MA of 91.03, indicating a neutral trend. The MACD of 1.13 indicates Positive momentum. The RSI at 53.63 is Neutral, neither overbought nor oversold. The STOCH value of 58.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for JP:4586.
Medrx Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | ¥5.70B | -45.84 | ― | 3.21% | 0.60% | -131.22% | |
52 Neutral | ¥7.92B | -8.71 | -54.56% | ― | 32.42% | 61.00% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | ¥4.47B | -4.64 | ― | ― | 167.44% | 49.38% | |
44 Neutral | ¥5.66B | -7.00 | ― | ― | 364.72% | 18.43% | |
41 Neutral | ¥3.44B | -1.37 | ― | ― | ― | -5.66% | |
40 Neutral | ¥4.97B | -0.62 | ― | ― | -37.69% | 1.85% |
* Healthcare Sector Average
JP:4586
Medrx Co., Ltd.
67.00
-44.00
-39.64%
JP:4597
Solasia Pharma KK
30.00
-7.00
-18.92%
JP:4539
Nippon Chemiphar Co., Ltd.
1,574.00
3.84
0.24%
JP:4582
Symbio Pharmaceuticals Limited
63.00
-85.00
-57.43%
JP:4883
Modalis Therapeutics Corporation
33.00
-54.00
-62.07%
JP:4892
Cyfuse Biomedical K.K.
570.00
-52.00
-8.36%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.